The aryl hydrocarbon receptor in tumor immunity

The aryl hydrocarbon receptor (AHR) binds environmental toxins and mediates immune regulation. The tryptophan metabolite kynurenine has now been identified as an endogenous ligand of the human AHR constitutively produced by gliomas and other types of cancer via tryptophan-2,3-dioxygenase (TDO), ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Platten, Michael, Litzenburger, Ulrike, Wick, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382870/
https://www.ncbi.nlm.nih.gov/pubmed/22737628
http://dx.doi.org/10.4161/onci.19071
_version_ 1782236563900465152
author Platten, Michael
Litzenburger, Ulrike
Wick, Wolfgang
author_facet Platten, Michael
Litzenburger, Ulrike
Wick, Wolfgang
author_sort Platten, Michael
collection PubMed
description The aryl hydrocarbon receptor (AHR) binds environmental toxins and mediates immune regulation. The tryptophan metabolite kynurenine has now been identified as an endogenous ligand of the human AHR constitutively produced by gliomas and other types of cancer via tryptophan-2,3-dioxygenase (TDO), thereby suppressing antitumor immune responses via the AHR. Thus, this pathway represents an important novel target for cancer immunotherapy.
format Online
Article
Text
id pubmed-3382870
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33828702012-06-26 The aryl hydrocarbon receptor in tumor immunity Platten, Michael Litzenburger, Ulrike Wick, Wolfgang Oncoimmunology Author's View The aryl hydrocarbon receptor (AHR) binds environmental toxins and mediates immune regulation. The tryptophan metabolite kynurenine has now been identified as an endogenous ligand of the human AHR constitutively produced by gliomas and other types of cancer via tryptophan-2,3-dioxygenase (TDO), thereby suppressing antitumor immune responses via the AHR. Thus, this pathway represents an important novel target for cancer immunotherapy. Landes Bioscience 2012-05-01 /pmc/articles/PMC3382870/ /pubmed/22737628 http://dx.doi.org/10.4161/onci.19071 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Platten, Michael
Litzenburger, Ulrike
Wick, Wolfgang
The aryl hydrocarbon receptor in tumor immunity
title The aryl hydrocarbon receptor in tumor immunity
title_full The aryl hydrocarbon receptor in tumor immunity
title_fullStr The aryl hydrocarbon receptor in tumor immunity
title_full_unstemmed The aryl hydrocarbon receptor in tumor immunity
title_short The aryl hydrocarbon receptor in tumor immunity
title_sort aryl hydrocarbon receptor in tumor immunity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382870/
https://www.ncbi.nlm.nih.gov/pubmed/22737628
http://dx.doi.org/10.4161/onci.19071
work_keys_str_mv AT plattenmichael thearylhydrocarbonreceptorintumorimmunity
AT litzenburgerulrike thearylhydrocarbonreceptorintumorimmunity
AT wickwolfgang thearylhydrocarbonreceptorintumorimmunity
AT plattenmichael arylhydrocarbonreceptorintumorimmunity
AT litzenburgerulrike arylhydrocarbonreceptorintumorimmunity
AT wickwolfgang arylhydrocarbonreceptorintumorimmunity

Ejemplares similares